Tripeptide-29 Limited Evidence

What It Is

Tripeptide-29 is the International Nomenclature of Cosmetic Ingredients (INCI) designation for a synthetic short peptide consisting of three amino acid residues in a fixed sequence: glycine, L-proline, and trans-4-hydroxy-L-proline (Gly-Pro-Hyp). The molecule has a molecular weight of approximately 285.3 daltons and the molecular formula C₁₂H₁₉N₃O₅ (CAS Registry Number 2239-67-0). It is supplied to formulators as a white-to-off-white powder, typically >95% purity by HPLC, and sold under cosmetic raw-material trade names such as AC Collagen Prepeptide PF and Collagen Tripeptide F.

The biological rationale for Tripeptide-29 begins with the structure of native collagen. Collagen — the most abundant protein in the human body and the dominant structural component of dermis, tendon, ligament, bone, and cartilage — is built from polypeptide alpha chains organized as a repeating Gly-X-Y triplet, where X is most often proline and Y is most often 4-hydroxyproline. Surveys of the collagen sequence database show that of the more than 400 possible Gly-X-Y triplets, only a limited subset appear in significant numbers, and Gly-Pro-Hyp is the single most abundant triplet across fibrillar collagens. Gly-Pro-Hyp is, in a literal sense, the minimal repeating signal unit of mature collagen architecture.

In cosmetic formulation, the Tripeptide-29 thesis is matrikine signaling: small collagen-derived fragments that escape complete proteolytic clearance can engage cell-surface receptors on dermal fibroblasts and signal a "tissue-needs-collagen" state, prompting fibroblasts to ramp up procollagen synthesis. The classical matrikine literature, established for fragments such as the C-terminal nonapeptide of type IV collagen and the famous palmitoyl-pentapeptide-4 (Matrixyl) sequence Lys-Thr-Thr-Lys-Ser, frames small collagen fragments as endogenous wound-healing signals. Tripeptide-29 is positioned within this framework as the minimal, most-conserved collagen fragment carrier of that signal.

Tripeptide-29 should be distinguished from several adjacent products that often share marketing copy. It is not a hydrolyzed collagen, although hydrolyzed collagen contains Gly-Pro-Hyp among many other peptides. It is not Pro-Hyp, the dipeptide collagen-fragment that has accumulated the most direct fibroblast in vitro evidence. It is not palmitoyl-tripeptide-1, palmitoyl-tripeptide-5, or any of the lipidated tripeptide derivatives that travel under "Tripeptide" naming with different sequences. It is not collagen tripeptide hydrolysates (CTPs), which are mixtures of small peptides enriched in Gly-Pro-Hyp but not pure Gly-Pro-Hyp. Read INCI labels carefully — "Tripeptide-29" is sequence-defined as Gly-Pro-Hyp; everything else is a different molecule with a different evidence base.

As a cosmetic ingredient, Tripeptide-29 sits in an unusual evidence gap. The mechanistic primary literature on Gly-Pro-Hyp is reasonably substantial — absorption studies, fibroblast culture studies, structural biology of the collagen triple helix, and wound-healing studies all reference the GPH triplet. The clinical literature on what happens when you put Tripeptide-29 in a face cream and apply it to humans is essentially non-existent at the level of randomized controlled trial evidence in PubMed-indexed peer-reviewed dermatology journals. This profile attempts to honestly bridge that gap.

Mechanism of Action

The mechanistic claims for Tripeptide-29 in topical cosmetics are extrapolated from three converging streams of evidence: structural biology of native collagen, in vitro fibroblast pharmacology of small collagen-derived peptides, and the broader matrikine-signaling literature. None of these streams was generated by applying Tripeptide-29 to human skin in a controlled trial, and the leap from "Gly-Pro-Hyp does X in cell culture" to "Tripeptide-29 in a serum does X in human skin" is not trivial.

• Most-conserved collagen triplet — Gly-Pro-Hyp is the single most abundant Gly-X-Y triplet in the fibrillar collagens (types I, II, III) that dominate dermal extracellular matrix. The 1998 Gly-X-Y frequency analysis (Ramshaw, Shah, Brodsky, J Struct Biol; PMID 9724608) established that of the >400 theoretically possible Gly-X-Y combinations, a small set predominate, with Gly-Pro-Hyp at the top. This statistical centrality is the foundation of Tripeptide-29's "minimal collagen signal" framing.
• Triple-helix stabilizer — Hydroxyproline at the Y position contributes ring-pucker hydrogen-bonding stability to the collagen triple helix; Gly-Pro-Hyp segments are the most thermally stable individual triplets and serve as the host scaffold in collagen-mimetic peptide research. This biophysical centrality of the GPH motif is a real, replicated finding from decades of structural biology.
• Plasma appearance after oral collagen ingestion — When humans consume hydrolyzed collagen, Gly-Pro-Hyp is one of approximately 17 collagen-derived peptide species that transiently appears in peripheral plasma at low micromolar concentrations within 1–2 hours, alongside the more abundant Pro-Hyp dipeptide (Iwai et al., 2005, PMID 16076145; Yamamoto et al., 2016, J Agric Food Chem; Sontakke et al., 2016, PMID 27573716). This documents systemic absorption after oral intake; it does not directly address topical penetration.
• Resistance to plasma peptidases — The Hyp residue confers striking resistance to standard plasma exopeptidases, allowing Gly-Pro-Hyp and Pro-Hyp to persist in plasma where most di- and tripeptides would not. This is mechanistically why GPH and Pro-Hyp are detectable at all after oral collagen — most other peptides are degraded within minutes (Iwai 2005, PMID 16076145).
• Fibroblast proliferation signal — indirectly through Pro-Hyp — When Gly-Pro-Hyp is delivered to skin (via plasma after oral ingestion, or hypothetically via topical penetration), much of it is hydrolyzed to Pro-Hyp by skin and plasma peptidases. Pro-Hyp has been shown in cultured fibroblast systems to enhance proliferation of mouse skin fibroblasts (Shigemura et al., 2009, J Agric Food Chem 57:444) and to enhance cell migration and hyaluronic acid synthesis in human dermal fibroblasts (Ohara et al., 2010, J Dermatol Sci). Gly-Pro-Hyp itself appears to act partly as a Pro-Hyp pro-peptide and partly as an independent signal (Yamamoto et al., 2016 — Gly-Pro-Hyp transported into skin via bloodstream; central activity of GPH similar to collagen degradation product mixture).
• p75NTR-positive fibroblast subset — Pro-Hyp appears to selectively engage a p75 neurotrophin-receptor-positive subset of mouse skin fibroblasts (Asai et al., 2020, J Funct Foods), proposing a mesenchymal-stem-cell-like progenitor target rather than blanket fibroblast stimulation. The implication is that the matrikine signal acts on wound-healing-competent fibroblast progenitors rather than the resident dermal fibroblast pool.
• Type I procollagen mRNA upregulation (manufacturer in vitro data) — Cosmetic raw-material technical data sheets for Tripeptide-29 (Active Concepts, ChemiNova, and similar) report dose-dependent upregulation of COL1A1 and/or COL1A2 mRNA in cultured fibroblasts at micromolar concentrations of GPH. These data are sponsor-generated, generally not peer-reviewed, and should be read as suggestive rather than confirmed.
• MMP balance modulation (claimed) — Some manufacturer literature attributes a downregulation of matrix metalloproteinase 1 (MMP-1; interstitial collagenase) and matrix metalloproteinase 3 (MMP-3; stromelysin-1) to GPH exposure in fibroblasts. The hypothesis is intuitive — a "collagen abundant" signal would logically downregulate collagenase output to preserve newly synthesized matrix — but independent peer-reviewed verification is sparse for the pure tripeptide.
• Anti-photoaging signal in collagen-hydrolysate models — Oral and dietary collagen-hydrolysate exposure in UVB-irradiated hairless-mouse models has shown reduction of skin wrinkle formation, preservation of dermal collagen fiber organization, and downregulation of MMP-2, MMP-9, MMP-3, and MMP-13 (Lee et al., Pak et al., Chae et al., 2023, J Med Food). The active fraction in these mouse studies is collagen-tripeptide-enriched and includes Gly-Pro-Hyp; deconvolution to pure Tripeptide-29 vs the broader hydrolysate is not clean.
• GPRC6A speculation — Some in vitro work proposes that small collagen-derived peptides may engage GPRC6A or other amino-acid-sensing G-protein-coupled receptors as part of their mechanism of action. This is hypothetical for Gly-Pro-Hyp specifically; no rigorous receptor-binding study with Tripeptide-29 as ligand has been published in a top-tier pharmacology journal.
• Platelet-collagen recognition (caveat) — In an entirely separate context, Gly-Pro-Hyp is the recognition motif for platelet glycoprotein VI (GPVI), the platelet collagen receptor responsible for collagen-induced platelet activation in hemostasis (Smethurst et al., 1999, PMID 10341844). This is a hemostasis biology fact, not a topical-cosmetic concern at use levels — but it is the cleanest published example of a cell-surface receptor that specifically recognizes the GPH triplet.
• Topical penetration — the biggest open question — At 285 Da, Tripeptide-29 is substantially below the often-cited 500-Da rule of thumb for transepidermal penetration of small molecules through intact stratum corneum. Manufacturers therefore claim adequate penetration for dermal fibroblast engagement. There is, however, no peer-reviewed Franz-cell or in vivo human skin-permeation study published for Tripeptide-29 specifically. Whether topically applied GPH actually reaches viable epidermal layers and the papillary dermis at meaningful concentrations is, for now, an extrapolation from molecular weight rather than a measured fact.
• Bottom line on mechanism — Gly-Pro-Hyp is a biologically meaningful collagen fragment with a real, documented presence in plasma after oral collagen ingestion and a plausible, partially documented matrikine-signaling profile in fibroblast culture. The leap to "topical Tripeptide-29 in a serum upregulates dermal collagen synthesis in human skin" is not supported by direct evidence; it is supported by mechanistic plausibility and analogy.

What the Research Shows

Tripeptide-29's research base is unusual: the underlying molecule (Gly-Pro-Hyp) has substantial primary biochemistry, biophysics, and absorption literature, but the finished cosmetic ingredient has essentially no peer-reviewed clinical trial literature in human skin. This section separates the two cleanly.

• Gly-Pro-Hyp absorption — Iwai 2005 — The pivotal study by Iwai and colleagues (Iwai et al., J Agric Food Chem, 2005; PMID 16076145) demonstrated that ingestion of 9.4–23 g of gelatin hydrolysate in healthy humans produces transient elevations of hydroxyproline-containing peptides in peripheral plasma reaching 20–60 nmol/mL within 1–2 hours. Identified peptide species included Pro-Hyp (the dominant constituent), Ala-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, and Phe-Hyp. This established the existence of food-derived collagen peptides in human circulation as a measurable phenomenon.
• Gly-Pro-Hyp enrichment in skin — Yamamoto 2016 — Yamamoto et al. (J Agric Food Chem 2016) extended the Iwai work by showing that ingestion of collagen tripeptide preparations leads to plasma enrichment of Gly-Pro-Hyp specifically (not just Pro-Hyp), and that GPH and its hydrolytic product Pro-Hyp are transported to the skin in mouse models. The study identified 17 collagen-derived peptide species in plasma, with GPH the most enriched after CTP ingestion.
• Gly-Pro-Hyp / Pro-Hyp absorption pharmacokinetics — Sontakke 2016 — Sontakke et al. (PMID 27573716) characterized the enzymatic stability, intestinal permeability, and absorption of GPH and Pro-Hyp in rat models, reporting differential bioavailability of the two peptides (Pro-Hyp ~19% vs GPH ~4%) and confirming biotransformation of GPH to Pro-Hyp in vivo. Relevant for understanding what circulating species actually reaches peripheral tissue.
• Pro-Hyp fibroblast proliferation — Shigemura 2009 — Shigemura et al. (J Agric Food Chem 2009;57:444-449) demonstrated that Pro-Hyp dose-dependently increases the migration and growth of fibroblasts from mouse skin in collagen-gel culture. This is the cleanest single-paper mechanistic basis for the matrikine claim, although the active species in this assay is Pro-Hyp (the dipeptide), not GPH (the tripeptide). Subsequent work has shown some fibroblast cell lines do not respond to Pro-Hyp, complicating the "general fibroblast stimulator" narrative.
• Pro-Hyp / Hyp-Gly fibroblast verification with hydroxyprolyl-peptide-free serum — Asai et al. (Int J Mol Sci 2020, 21:229) revisited the fibroblast proliferation claim using fetal bovine serum specifically depleted of endogenous hydroxyprolyl peptides. The replication confirmed an effect in primary cultured mouse skin fibroblasts but raised concerns about prior literature that did not control for background hydroxyprolyl peptide content in standard FBS — a methodological caveat that should be applied conservatively when reading older positive in vitro literature.
• p75NTR fibroblast specificity — Asai 2020 (J Funct Foods) — Asai and colleagues (Mouse skin fibroblasts with mesenchymal stem cell marker p75 neurotrophin receptor proliferate in response to prolyl-hydroxyproline) reported that Pro-Hyp specifically engages a small p75NTR-positive subpopulation of fibroblasts, suggesting the matrikine effect targets wound-healing progenitor cells rather than the broad fibroblast population. Relevant for re-framing the magnitude of the expected effect in normal, non-injured skin.
• Gly-X-Y collagen sequence frequency — Ramshaw 1998 — Ramshaw, Shah, and Brodsky (PMID 9724608) established the canonical Gly-X-Y triplet frequency analysis for collagen, demonstrating Gly-Pro-Hyp's dominant frequency in fibrillar collagens. This is the structural-biology paper that grounds the "GPH is the most representative collagen triplet" framing used in cosmetic marketing.
• Gly-Pro-Hyp / GPVI platelet recognition — Smethurst 1999 — Smethurst et al. (PMID 10341844) demonstrated that platelet glycoprotein VI specifically recognizes the Gly-Pro-Hyp sequence to mediate collagen-induced platelet activation. Mechanistically interesting because it confirms that there exist mammalian cell-surface receptors that distinguish GPH from related triplets (Gly-Pro-Pro, Gly-Pro-Ala, Gly-Pro-Arg) at high specificity. This receptor is platelet-restricted and not a topical-cosmetic safety concern at use levels, but it grounds the principle that GPH is a recognized signal motif.
• Broader oral collagen-peptide-hydrolysate skin literature — Proksch 2014 — Proksch et al. (Skin Pharmacol Physiol 2014;27(1):47-55; PMID 23949208) randomized 69 women aged 35–55 to 2.5 g or 5 g per day of a specific bioactive collagen peptide (Verisol) or placebo for 8 weeks. Statistically significant improvement in skin elasticity in both treatment groups versus placebo at week 8. Critical caveat: Verisol is a hydrolyzed collagen mixture (oral, ingested), not Tripeptide-29 in a topical cosmetic; the connection to Tripeptide-29 is the presence of GPH among the active species in plasma after Verisol ingestion.
• Asserin 2015 oral collagen RCT — PMID 26362110 — Asserin et al. (J Cosmet Dermatol 2015;14:291-301) ran two placebo-controlled trials on oral collagen peptide supplementation, reporting significant 8-week improvement in skin hydration and 4-week improvement in dermal collagen density and decrease in collagen fragmentation by reflectance confocal microscopy. Again, oral hydrolysate, not Tripeptide-29 — but representative of the broader collagen-peptide skin literature on which Tripeptide-29 marketing leans.
• Bolke 2019 collagen supplement RCT — PMID 31627309 — Bolke et al. (Nutrients 2019;11(10):2494) randomized to a collagen-peptide-containing nutricosmetic blend versus placebo, reporting improvement in skin hydration, elasticity, roughness, and density. Multi-ingredient formulation makes attribution to collagen peptides specifically (let alone GPH) impossible.
• Choi 2019 systematic review — PMID 30681787 — Choi et al. (J Drugs Dermatol 2019;18(1):9-16) systematically reviewed 11 randomized controlled trials of oral collagen supplementation for dermatological applications (805 total patients; 8 trials of collagen hydrolysate 2.5–10 g/day for 8–24 weeks; 2 trials of collagen tripeptide 3 g/day for 4–12 weeks; 1 trial of collagen dipeptide). Conclusion: preliminary results promising for skin elasticity and hydration; methodological quality variable; no trial in this systematic review tested topical Tripeptide-29.
• Kim 2018 LMWCP RCT (Nutrients) — Kim et al. (Nutrients 2018;10:826) tested an oral low-molecular-weight collagen peptide preparation containing >15% Gly-X-Y tripeptide content including 3% Gly-Pro-Hyp, randomized double-blind placebo-controlled in 64 subjects for 12 weeks. Improvement in skin hydration, elasticity, and wrinkling. The closest the broader literature gets to a "GPH-enriched preparation" RCT — but still oral, still a multi-component preparation, and still not topical Tripeptide-29.
• Kim 2022 LMWCP RCT — PMID 36516059 — Kim et al. (J Med Food 2022) reported a randomized double-blind placebo-controlled trial of low-molecular-weight collagen peptides for photoaged facial skin, demonstrating improvements in wrinkles, elasticity, hydration, and barrier integrity. Same caveats — oral, multi-component, not topical Tripeptide-29.
• Lintner 2005 collagen-like hexapeptide topical — PMID 15648443 — A double-blind clinical study of a synthetic collagen-like hexapeptide (not Tripeptide-29) at 3% topical formulation versus placebo in 20 women aged 40–62 reported antiwrinkle effect on Crow's feet area. This is the closest precedent in the published literature for a "synthetic collagen-fragment topical with measured antiwrinkle effect," and it is not Tripeptide-29 — but it documents that the general approach has a non-zero probability of producing a measurable effect in human skin.

Human Data

To be unambiguous: at the time of this writing, there are no published, peer-reviewed, randomized, placebo-controlled clinical trials of finished topical cosmetic formulations containing Tripeptide-29 (Gly-Pro-Hyp) as the named active ingredient indexed in PubMed. Effect claims for Tripeptide-29 in topical cosmetics derive from three indirect evidence streams:

• Stream 1 — Oral collagen-peptide hydrolysate human RCTs. A substantial body of randomized placebo-controlled trials has tested orally ingested collagen hydrolysates (typically 2.5–10 g per day for 8–24 weeks) for skin hydration, elasticity, density, and wrinkle parameters. Representative pivotal studies include Proksch 2014 (PMID 23949208), Asserin 2015 (PMID 26362110), Bolke 2019 (PMID 31627309), Kim 2018 (Nutrients 10:826), Schunck 2015 cellulite arm (PMID 26561784), Genovese 2018 (PMID 30122200), and Kim 2022 (PMID 36516059). Effect sizes are modest but reasonably consistent across multiple independent RCTs, particularly for skin elasticity and hydration. None of these trials were testing Tripeptide-29 as a finished cosmetic. They were testing oral hydrolysates that contain GPH among many other peptide species, after gut digestion and systemic absorption.
• Stream 2 — Pharmacokinetic studies of GPH in human plasma. Iwai 2005 (PMID 16076145), Yamamoto 2016 (J Agric Food Chem), Sontakke 2016 (PMID 27573716), and the npj Science of Food 2022 paper on Gly-3Hyp-4Hyp document that GPH and related collagen tripeptides are absorbed from the gut and reach peripheral plasma at low micromolar concentrations after oral collagen ingestion. This documents systemic exposure, not topical penetration or dermal delivery from a cosmetic vehicle. The translation to topical use is an extrapolation, not a measurement.
• Stream 3 — Choi 2019 systematic review, oral collagen tripeptide subset. Within the Choi systematic review (PMID 30681787), two of the 11 included trials specifically tested oral "collagen tripeptide" preparations (3 g per day for 4–12 weeks) with reported improvement in skin elasticity and hydration. These trials are on enriched-tripeptide oral hydrolysates, not pure Tripeptide-29 and not topical formulations.
• Indirect topical precedent. Lintner et al. (PMID 15648443) tested a 3% topical synthetic collagen-like hexapeptide (different sequence, not Tripeptide-29) versus placebo in 20 women, reporting antiwrinkle effect at the Crow's feet area. This is the published precedent that small synthetic collagen-fragment peptides applied topically can produce measurable cosmetic outcomes in controlled studies — a precedent, not direct evidence for Tripeptide-29 specifically.
• Tangential finished-product trials. A small set of cosmetic-industry abstracts and posters describe finished products containing Tripeptide-29 alongside other actives (peptide complexes, hyaluronic acid, niacinamide, retinol) with reported subject-graded improvements over baseline. These are typically open-label, sponsor-conducted, and not peer-reviewed in PubMed-indexed journals; attribution of effect to Tripeptide-29 specifically is impossible given multi-ingredient formulations.

The honest summary: when a Tripeptide-29 marketing claim says "clinically proven," the underlying citation chain almost always traces back to (a) oral collagen-hydrolysate human RCTs that did not test the cosmetic, (b) in vitro fibroblast assays on Pro-Hyp or GPH that did not test human skin, or (c) sponsor-conducted unpublished consumer-perception studies of finished products containing many ingredients. None of those is the same thing as a peer-reviewed RCT of Tripeptide-29 in a vehicle versus the same vehicle without it. Until such a trial exists, "Limited Evidence" is the accurate characterization.

Dosing from the Literature

Tripeptide-29 is a topical cosmetic ingredient. There is no oral, injected, intranasal, or any other systemic dosing pathway in cosmetic use. The "dose" is the finished-formula concentration (% w/w) and the application frequency. Cosmetic raw-material technical data sheets and INCI-database guidance converge on the following ranges:

For formulators working from concentrated stock solutions, the typical commercial Tripeptide-29 raw material is supplied either as 100% pure peptide powder (for in-house dilution) or as 0.5–1% aqueous solutions in preserved water (for direct addition to oil-in-water emulsion phases). Powder is preferred for accurate active-content control; aqueous solutions are preferred for ease of incorporation and consistent dispersion.

Reconstitution & Storage

Tripeptide-29 is supplied to formulators as a powder cosmetic raw material and incorporated into finished products by formulation chemists rather than reconstituted by end users. The handling guidance below is for cosmetic-formulation R&D, indie skincare manufacturing, and compounded specialty serums. End consumers purchasing finished products do not need to reconstitute anything.

For the small subset of users compounding their own peptide serums from raw material (cosmetic chemistry hobbyists, indie formulators, compounding pharmacists): start with a pre-dissolved 1% aqueous stock solution in preserved deionized water at pH 5.5–6.0, then dilute into the finished formula at the desired use level. Validate finished-product pH after addition. Validate microbiological stability with challenge testing per ISO 11930 if intending to share or sell. Never formulate cosmetic peptide products without a preservation system — peptide solutions support rapid microbial growth.

→ Use the Kalios Dosing Calculator for cosmetic concentration conversions

Side Effects & Risks

Tripeptide-29 has a reassuringly clean safety profile at conventional cosmetic use levels. It is, biochemically, a fragment of a protein (collagen) that constitutes ~30% of the body's total protein content; the molecule is not foreign to human biology in any meaningful sense. The risks are correspondingly modest:

• Most common — none — At conventional 1–5% topical use levels in well-formulated cosmetic vehicles, Tripeptide-29 is broadly well tolerated with no characteristic adverse-effect pattern reported in cosmetic-industry surveillance. Most consumer complaints with Tripeptide-29-containing products track to other ingredients in the formulation (preservatives, fragrance, other actives) rather than to the peptide itself.
• Contact sensitization (rare) — Any topical protein or peptide ingredient carries a small theoretical risk of contact-allergic sensitization, particularly in individuals with prior atopic dermatitis or known peptide / protein hypersensitivity. Reports specific to Tripeptide-29 in the dermatology contact-allergy literature are essentially absent. Patch testing prior to first use is reasonable for individuals with known multiple-cosmetic-ingredient sensitivities.
• Vehicle-driven irritation — Most adverse events with Tripeptide-29-containing serums are driven by other formulation components — alcohol denat at high percentages, propylene glycol in sensitive subjects, fragrance, essential oils, low-pH active blends — rather than by the peptide. When evaluating a new product, isolate the variable: try a vehicle-only patch test first, then introduce the peptide-containing version.
• No systemic safety data — Because Tripeptide-29 is used topically in cosmetics, there is no oral, IV, IM, or subcutaneous safety pharmacology dataset. The body's exposure to ingested Gly-Pro-Hyp (from hydrolyzed collagen supplementation) has been well characterized and is reassuringly safe at gram-level daily intakes — but inferring safety of topical Tripeptide-29 from oral collagen hydrolysate evidence is a translation, not a direct measurement.
• Pregnancy and lactation — Topical peptides are generally regarded as low-risk in pregnancy and lactation given minimal systemic absorption from intact stratum corneum, and Tripeptide-29 specifically is a fragment of an endogenous human protein. Definitive pregnancy-safety data does not exist for Tripeptide-29; consult an obstetric provider for individualized guidance, particularly when considering multi-active formulations that may include other ingredients (retinoids, hydroquinone, salicylic acid) with established pregnancy avoidance recommendations.
• Pediatric use — Cosmetic use in pediatric populations is uncommon and not specifically studied. There is no biological reason to expect harm from a topical collagen fragment in children, but cosmetic regulatory guidance generally limits pediatric cosmetic claims absent specific safety substantiation.
• Drug interactions — None reported. Topical Tripeptide-29 does not engage cytochrome P450 enzymes, transporters, or other systemic drug-metabolism pathways at biologically meaningful concentrations. Combination with other topical actives (retinoids, vitamin C, niacinamide, hyaluronic acid, ceramides, copper peptides, AHAs/BHAs) is generally compatible at appropriate formulation pH; sequencing in a multi-step routine is more about texture and absorption than chemical interaction.
• Photosensitivity — Not photosensitizing. Unlike retinoids, AHAs, or hydroquinone, Tripeptide-29 does not increase UV sensitivity. Standard daily SPF guidance applies regardless.
• WADA / sport considerations — Tripeptide-29 is not specifically named on the World Anti-Doping Agency Prohibited List. As a topical cosmetic ingredient with no documented systemic absorption to plasma at meaningful concentrations from cosmetic application, it has no plausible doping relevance. Athletes with sport-specific concerns about cosmetic ingredients should consult their federation.
• Theoretical concerns at supraphysiological use — All hypothetical and not supported by evidence: matrikine-class peptides with collagen-stimulating signals could theoretically contribute to keloid or hypertrophic-scar tendency in predisposed individuals; could theoretically interact with active wound-healing pharmacology; could theoretically promote dermal proliferation that is undesirable in specific clinical contexts (active dermatologic disease). None of these has been documented in cosmetic use; all are reasons to consult a dermatologist before incorporating a new active in the context of active skin pathology.
• Quality / purity concerns — As with all peptide ingredients, raw-material quality varies across suppliers. Reputable cosmetic raw-material suppliers (Bachem, Active Concepts, Peptide Institute Inc., MedChemExpress) provide HPLC purity certificates of analysis (typically >95% by HPLC). Lower-grade material may contain higher levels of synthesis byproducts, residual solvents, or microbial contamination. Consumers buying finished products from established cosmetic brands generally do not need to worry about this; consumers buying raw peptide powder for self-formulation should insist on a current COA from the supplier.

Bloodwork & Monitoring

Topical cosmetic use of Tripeptide-29 at conventional concentrations does not warrant any laboratory monitoring. There is no documented systemic absorption from intact-skin cosmetic application sufficient to perturb any standard laboratory parameter. The following section is included for completeness — for the unusual scenarios where systemic exposure could conceivably matter (compromised skin barrier, very large surface area treatment, hypothetical injected use that is not recommended) — and as conservative guidance for consumers who simply prefer baseline data on any new active they introduce.

• Standard cosmetic use — no monitoring required — Topical Tripeptide-29 in serums, creams, eye products, and masks at conventional 1–5% use levels does not require baseline labs, follow-up labs, or any other monitoring.
• If hypothetically systemic — CMP and CBC baseline — A comprehensive metabolic panel and complete blood count would be conventional baseline labs before any meaningful systemic peptide exposure. There is no specific Tripeptide-29-related biomarker to track on these panels.
• Hydroxyproline excretion — Urinary hydroxyproline is occasionally measured as a surrogate for collagen turnover in research contexts. Oral collagen-hydrolysate ingestion transiently elevates urinary hydroxyproline excretion within 24 hours of intake (well documented in the Iwai 2005 lineage of pharmacokinetic studies). Topical cosmetic use would not be expected to perturb this measurement; the assay is not clinically standard outside research settings.
• Type I procollagen markers (PINP, P1NP) — Serum N-terminal propeptide of type I collagen (P1NP) is a clinical bone-formation marker used in osteoporosis monitoring. It reflects systemic type I collagen synthesis (overwhelmingly bone-derived). It is not a useful marker of cosmetic dermal-collagen response and would not be expected to change with topical Tripeptide-29 at any dose.
• Skin biophysical instrumentation (research / clinic only) — In a research or specialized dermatology-clinic context, the relevant "monitoring" instruments for a Tripeptide-29 efficacy assessment would be Cutometer (skin elasticity), Corneometer (hydration / TEWL), Visiometer (wrinkle depth), high-resolution ultrasound (dermal thickness and density), confocal reflectance microscopy (dermal collagen network), and standardized digital photography under controlled lighting at fixed timepoints (baseline, 4 weeks, 8 weeks, 12 weeks). These are research methodologies, not consumer monitoring.
• Self-assessment — For consumer use, the practical "monitoring" approach is: standardized photography in consistent lighting at baseline, week 4, week 8, week 12, and week 24; subjective tracking of skin tightness / hydration / fine line depth; symmetric split-face comparison (apply to one half of the face for a defined trial period) is a useful informal home methodology. Allow 8–12 weeks minimum before judging effect — dermal collagen turnover is slow, and matrikine-driven changes are not meant to be visible in the first two weeks.
• Allergy / contact dermatitis surveillance — If introducing any new cosmetic active, perform a 48-hour patch test on a small skin area (inner forearm or behind the ear) before facial application. Discontinue at first sign of erythema, induration, vesiculation, or unexplained itch. Refer to dermatology for patch testing per the North American Contact Dermatitis Group standard series if persistent reaction develops.

Commonly Stacked With

Tripeptide-29 is rarely used as a stand-alone active. In typical cosmetic formulations, it sits alongside one or more of the following — paired actives that target different aspects of the dermal aging cascade or that contribute complementary skin-comfort and barrier-supporting effects.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Tripeptide-29 often also look at these:

Next Steps

Key References

1. Iwai K, Hasegawa T, Taguchi Y, Morimatsu F, Sato K, Nakamura Y, Higashi A, Kido Y, Nakabo Y, Ohtsuki K. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. J Agric Food Chem. 2005;53(16):6531-6536. PMID: 16076145. doi: 10.1021/jf050206p. (The pivotal pharmacokinetic study documenting Pro-Hyp, Ala-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, and related collagen-derived peptides in human plasma at 20–60 nmol/mL after gelatin hydrolysate ingestion.)
2. Sontakke SB, Jung JH, Piao Z, Chung HJ. Orally Available Collagen Tripeptide: Enzymatic Stability, Intestinal Permeability, and Absorption of Gly-Pro-Hyp and Pro-Hyp. J Agric Food Chem. 2016;64(38):7127-7133. PMID: 27573716. (Differential bioavailability of GPH vs Pro-Hyp; biotransformation of GPH to Pro-Hyp in rat absorption model.)
3. Shigemura Y, Iwai K, Morimatsu F, Iwamoto T, Mori T, Oda C, Taira T, Park EY, Nakamura Y, Sato K. Effect of Prolyl-hydroxyproline (Pro-Hyp), a food-derived collagen peptide in human blood, on growth of fibroblasts from mouse skin. J Agric Food Chem. 2009;57(2):444-449. doi: 10.1021/jf802785h. (Mouse skin fibroblast proliferation in response to Pro-Hyp — the cleanest single-paper basis for the matrikine fibroblast-stimulation claim for the collagen-tripeptide axis.)
4. Asai TT, Yoshikawa K, Sawada K, Fukamizu K, Koyama YI, Shigemura Y, Jimi S, Sato K. Mouse skin fibroblasts with mesenchymal stem cell marker p75 neurotrophin receptor proliferate in response to prolyl-hydroxyproline. J Funct Foods. 2020;66:103792. (p75NTR-positive fibroblast subset specificity for Pro-Hyp matrikine signal.)
5. Asai TT, Oikawa F, Yoshikawa K, Inoue N, Sato K. Food-Derived Collagen Peptides, Prolyl-Hydroxyproline (Pro-Hyp), and Hydroxyprolyl-Glycine (Hyp-Gly) Enhance Growth of Primary Cultured Mouse Skin Fibroblast Using Fetal Bovine Serum Free from Hydroxyprolyl Peptide. Int J Mol Sci. 2019;21(1):229. (Fibroblast assay replication with hydroxyprolyl-peptide-depleted FBS — important methodological control for the broader Pro-Hyp / GPH fibroblast literature.)
6. Ramshaw JA, Shah NK, Brodsky B. Gly-X-Y tripeptide frequencies in collagen: a context for host-guest triple-helical peptides. J Struct Biol. 1998;122(1-2):86-91. PMID: 9724608. (The canonical Gly-X-Y triplet frequency analysis establishing Gly-Pro-Hyp as the dominant collagen triplet — foundational structural-biology reference for Tripeptide-29 marketing.)
7. Smethurst PA, Onley DJ, Jarvis GE, O'Connor MN, Knight CG, Herr AB, Ouwehand WH, Farndale RW. Structural basis for the platelet-collagen interaction: the smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem. 2007;282(2):1296-1304. (Platelet GPVI / collagen Gly-Pro-Hyp recognition — documents that mammalian cell-surface receptors recognize the GPH triplet at high specificity.)
8. Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J. 1995;306(Pt 2):337-344. PMID: 7887888. (Earlier foundational work on GPH / platelet GpVI specificity; the 1999 Knight et al paper PMID 10341844 in Cardiovasc Res extended this analysis to confirm GPH as the specific activating motif.)
9. Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. PMID: 23949208. doi: 10.1159/000351376. (Pivotal oral collagen peptide RCT — 69 women, 8 weeks, significant skin elasticity improvement. Not Tripeptide-29 specific; representative of the broader collagen-peptide-hydrolysate evidence base.)
10. Asserin J, Lati E, Shioya T, Prawitt J. The effect of oral collagen peptide supplementation on skin moisture and the dermal collagen network: evidence from an ex vivo model and randomized, placebo-controlled clinical trials. J Cosmet Dermatol. 2015;14(4):291-301. PMID: 26362110. doi: 10.1111/jocd.12174. (Two RCTs of oral collagen peptide supplementation showing skin hydration, dermal collagen density, and reduced collagen fragmentation. Oral, not topical Tripeptide-29.)
11. Schunck M, Zague V, Oesser S, Proksch E. Dietary Supplementation with Specific Collagen Peptides Has a Body Mass Index-Dependent Beneficial Effect on Cellulite Morphology. J Med Food. 2015;18(12):1340-1348. PMID: 26561784. (Oral bioactive collagen peptides for cellulite morphology, 105 women, 6-month RCT. Representative of the broader oral collagen peptide RCT body of work.)
12. Bolke L, Schlippe G, Gerß J, Voss W. A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study. Nutrients. 2019;11(10):2494. PMID: 31627309. doi: 10.3390/nu11102494. (Multi-ingredient nutricosmetic RCT including collagen peptides; multi-component blend prevents attribution to GPH specifically.)
13. Choi FD, Sung CT, Juhasz ML, Mesinkovsk NA. Oral Collagen Supplementation: A Systematic Review of Dermatological Applications. J Drugs Dermatol. 2019;18(1):9-16. PMID: 30681787. (Systematic review of 11 RCTs of oral collagen supplementation, 805 patients; includes 2 collagen tripeptide trials. No included trial tested topical Tripeptide-29.)
14. Kim DU, Chung HC, Choi J, Sakai Y, Lee BY. Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2018;10(7):826. doi: 10.3390/nu10070826. (Oral LMWCP preparation containing >15% Gly-X-Y tripeptide content including 3% Gly-Pro-Hyp — closest the broader literature gets to a "GPH-enriched" oral RCT, still oral and still multi-component.)
15. Kim J, Lee SG, Lee J, Choi S, Suk J, Lee JH, Yang JH, Yang JS, Kim J. Oral Supplementation of Low-Molecular-Weight Collagen Peptides Reduces Skin Wrinkles and Improves Biophysical Properties of Skin: A Randomized, Double-Blinded, Placebo-Controlled Study. J Med Food. 2022;25(12):1146-1154. PMID: 36516059. (Photoaging RCT of LMWCP oral supplementation.)
16. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22(3):207-218. (Foundational matrikine-cosmetic-peptide review establishing the "small synthetic peptide as topical fibroblast signal" framework — palmitoyl-pentapeptide-4 / Matrixyl included.)
17. Aldag C, Nogueira Teixeira D, Leventhal PS. Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literature. Clin Cosmet Investig Dermatol. 2016;9:411-419. (Review of matrikine-class cosmetic peptide ingredients and their evidence base.)
18. Yamamoto S, Hayasaka F, Deguchi K, Okudera T, Furusawa T, Sakai Y. Absorption and plasma kinetics of collagen tripeptide after peroral or intraperitoneal administration in rats. Biosci Biotechnol Biochem. 2015;79(12):2026-2033. (Pharmacokinetic study of Gly-Pro-Hyp absorption after peroral and intraperitoneal administration; documents systemic exposure to GPH.)
19. Taga Y, Iwasaki Y, Shigemura Y, Mizuno K. Identification of a Highly Stable Bioactive 3-Hydroxyproline-Containing Tripeptide in Human Blood after Collagen Hydrolysate Ingestion. npj Sci Food. 2022;6(1):29. (Identification of Gly-3Hyp-4Hyp as a stable bioactive collagen tripeptide in human blood; chemoattractant for skin fibroblasts. Adjacent biology relevant to the broader collagen-tripeptide skin-effect mechanistic story.)
20. Hatanaka T, Kawakami K, Uraji M. Inhibitory effect of collagen-derived tripeptides on dipeptidylpeptidase-IV activity. J Enzyme Inhib Med Chem. 2014;29(6):823-828. (Documents enzymatic activity of Gly-Pro-Hyp, Gly-Ala-Hyp, and Gly-Pro-Ala collagen tripeptides on DPP-IV — shows GPH has measurable cell-relevant enzymatic activity beyond the matrikine-signaling claim.)
21. Ohara H, Ichikawa S, Matsumoto H, Akiyama M, Fujimoto N, Kobayashi T, Tajima S. Collagen-derived dipeptide, proline-hydroxyproline, stimulates cell proliferation and hyaluronic acid synthesis in cultured human dermal fibroblasts. J Dermatol. 2010;37(4):330-338. (Pro-Hyp dipeptide enhances proliferation and HA synthesis in human dermal fibroblasts at 200 nmol/mL — the strongest single piece of in vitro evidence for the matrikine-class signal in human skin cells.)
22. Hexsel D, Zague V, Schunck M, Siega C, Camargo FB Jr, Oesser S. Oral supplementation of specific bioactive collagen peptides reduces skin wrinkles and improves nail growth in women. J Cosmet Dermatol. 2017;16(4):520-526. PMID: 28786550. (Oral bioactive collagen peptides RCT in nail-brittleness — adjacent collagen-peptide cosmetic indication, representative of the wider field.)
23. Genovese L, Corbo A, Sibilla S. An Insight into the Changes in Skin Texture and Properties following Dietary Intervention with a Nutricosmeceutical Containing a Blend of Collagen Bioactive Peptides and Antioxidants. Skin Pharmacol Physiol. 2017;30(3):146-158. PMID: 30122200. (Nutricosmetic blend including collagen bioactive peptides; multi-ingredient formulation; representative of the broader nutricosmeceutical RCT literature.)
24. De Luca C, Mikhal'chik EV, Suprun MV, Papacharalambous M, Truhanov AI, Korkina LG. Skin Antiageing and Systemic Redox Effects of Supplementation with Marine Collagen Peptides and Plant-Derived Antioxidants: A Single-Blind Case-Control Clinical Study. Oxid Med Cell Longev. 2016;2016:4389410. (Marine collagen peptide oral supplementation skin study; representative of marine-collagen-peptide subset of the broader literature.)